Morgan Stanley lowered the firm’s price target on Myriad Genetics (MYGN) to $16 from $21 and keeps an Equal Weight rating on the shares after Q4 results were reported in-line with preliminary expectations and the company’s 2025 guidance range was reiterated. UnitedHealthcare (UNH) headwinds and a CEO transition point to near-term uncertainty, says the analyst, who argues that sustainable growth acceleration is “key to re-rating” of the shares.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on MYGN:
- Myriad Genetics price target lowered to $11.50 from $14 at Piper Sandler
- Myriad Genetics price target lowered to $11 from $13 at BofA
- Myriad Genetics Faces Financial Uncertainty Amid Potential Tax Law Changes
- Myriad Genetics Reports Strong Growth Amid Challenges
- Cautious Outlook for Myriad Genetics Amid Leadership Transition and Revised Growth Projections